Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Myelodysplastic Syndromes 26Leukemia, Myeloid, Acute 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Leukemia 23Anemia, Refractory, with Excess of Blasts 20Lymphoma 19Leukemia, Lymphocytic, Chronic, B-Cell 18Hodgkin Disease 18Lymphoma, Non-Hodgkin 17Myeloproliferative Disorders 16Anemia, Aplastic 16Multiple Myeloma 15Leukemia, Myelomonocytic, Chronic 14Leukemia, Myeloid, Chronic-Phase 13Leukemia, Myeloid, Accelerated Phase 13Burkitt Lymphoma 12Primary Myelofibrosis 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Dendritic Cell Sarcoma, Interdigitating 11Blast Crisis 11Myelodysplastic-Myeloproliferative Diseases 10Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 10Congenital Abnormalities 10Recurrence 9Lymphoma, Mantle-Cell 9Lymphoma, Large-Cell, Immunoblastic 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myelomonocytic, Juvenile 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8

Interventions

thymoglobulin 1fludarabine 1Rituximab 1Melphalan 1Levetiracetam 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Melphalan × Classical hematology × Clear all
NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
70 enrolled
CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡